Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 49Lung Neoplasms 12Neoplasms 8Lymphoma, Large-Cell, Anaplastic 8Neoplasm Metastasis 7Multiple Myeloma 6Lymphoma 6Granuloma, Plasma Cell 4Colorectal Neoplasms 4Adenocarcinoma 4Uveal Melanoma 3Neuroblastoma 3Melanoma 3Hematologic Neoplasms 3Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Recurrence 2Glioma 2Glioblastoma 2Carcinoma, Squamous Cell 2Carcinoma, Hepatocellular 2Carcinoma 2Breast Neoplasms 2ALK-positive NSCLC 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1

Interventions

Gemcitabine 13pembrolizumab 9Specimen Handling 9enfortumab vedotin 8Cisplatin 8Magnetic Resonance Spectroscopy 7avelumab 5Carboplatin 5vinflunine 4Nivolumab 4atezolizumab 3Immunoglobulin G 3Disulfides 3Biopsy 3eribulin 2cabozantinib 2Standard of Care 2Ramucirumab 2Radiotherapy 2Platinum 2Nephroureterectomy 2Ipilimumab 2Doxorubicin 2Docetaxel 2CTLA-4 Antigen 2Bortezomib 21,2-diaminocyclohexaneplatinum II citrate 2vandetanib 1tremelimumab 1tocilizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ureteral Neoplasms × Crizotinib × Clear all
NCT02612194 2022-11-03

LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer

Wake Forest University Health Sciences

Phase 2 Terminated
8 enrolled 16 charts
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡